Genomics, Circuits, and Pathways in Clinical Neuropsychiatry

Dr. Thomas Lehner is the Director of the Office for Genomics Research Coordination at the National Institute of Mental Health (NIMH), National Institutes of Health (NIH). He oversees and coordinates all efforts associated with genomics research for the NIMH and is the principal advisor to the NIMH Director and the NIMH Scientific Director for issues related to genetics and genomics. A native of Vienna, Austria, he received a Ph.D. in genetics from the University of Vienna and an MPH in Epidemiology from Columbia University. Since joining NIMH in 2004 Thomas has been instrumental in developing Team Science as a new paradigm for psychiatric genomics and forging international collaborative efforts and consortia. He has also been instrumental in developing and consolidating genomics resources for the research community through participation in developing NIH data sharing policies for genomics including the Genomic Data Sharing (GDS) policy and its implementation. Dr. Miller holds the A.W. and Mary Margaret Clausen Distinguished Professorship in Neurology at the University of California, San Francisco (UCSF). He directs the busy UCSF dementia center where patients in the San Francisco Bay Area and beyond receive comprehensive clinical evaluations. His goal is the delivery of model care to all of the patients who enter the clinical and research programs at the UCSF Memory and Aging Center (MAC).Dr. Miller is a behavioral neurologist focused on dementia with special interests in brain and behavior relationships as well as the genetic and molecular underpinnings of disease. His work in frontotemporal dementia (FTD) emphasizes both the behavioral and emotional deficits that characterize these patients, while simultaneously noting the visual creativity that can emerge in the setting of FTD. He is the principal investigator of the NIH-sponsored Alzheimer’s Disease Research Center (ADRC) and program project on FTD called Frontotemporal Dementia: Genes, Imaging and Emotions. He oversees a healthy aging program, which includes an artist in residence program. In addition, he helps lead two philanthropy-funded research consortia, the Tau Consortium and Consortium for Frontotemporal Research, focused on developing treatments for tau and progranulin disorders, respectively. Also, he works with the National Football League to help with the education and assessment of players related to brain health. Dr. Miller teaches extensively, runs the Behavioral Neurology Fellowship at UCSF, and oversees visits of more than 50 foreign scholars every year.Dr. Miller has received many awards including the Potamkin Award from the American Academy of Neurology, the Raymond Adams Lecture at the American Neurological Association, the Elliot Royer Award from the San Francisco Neurological community, the UCSF Annual Faculty Research Lectureship in Clinical Science, the UCSF Academic Senate Distinction in Mentoring Award, Distinguished Service to Minorities, from Charles Drew University, and the Gene D. Cohen Research Award in Creativity and Aging from the National Center for Creative Aging. He has authored The Human Frontal Lobes, The Behavioral Neurology of Dementia, Frontotemporal Dementia and over 600 other publications regarding dementia. He has been featured in Fortune magazine and The New York Times, as well as on "Charlie Rose," "PBS NewsHour" and other media. For more than three decades, Dr. Miller has been the scientific director for the philanthropic organization The John Douglas French Alzheimer’s Foundation, a private philanthropic organization that funds basic science research in Alzheimer’s disease.Matthew W. State MD, PhD, is a child psychiatrist and human geneticist studying pediatric neuropsychiatric syndromes. His lab focuses on gene discovery as a launching point for efforts to illuminate the biology of these conditions and to develop novel and more effective therapies. Dr. State received his undergraduate and medical degrees at Stanford University, completed his residency in psychiatry and fellowship in child psychiatry at the UCLA Neuropsychiatric Institute, and earned a PhD in genetics from Yale University. He was on the faculty at Yale from 2001 to 2013 where he was the Donald J. Cohen Professor of Child Psychiatry, Psychiatry and Genetics and the Co-Founder and Co-Director of the Yale Program on Neurogenetics. He is currently the Oberndorf Family Distinguished Professor and Chair of Psychiatry at UCSF and Director of the Langley Porter Psychiatric Institute and Hospital.

• Section 1 The Genome Tools and Methods1. The Newly Emerging View of the GenomeStephan Sanders2. Genetic EpidmeiologyKathleen Ries Merikangas3. Common VariationMark Daly4. Rare/Structural VariationDaniel Barrera and Jonathan Sebat 5. Epigenetics and EpigenomicsEric J. Nestler and John Greally 6. BioinformaticsShaun Purcell7. Imaging GenomicsPaul Matthew Thompson8. Stem Cell Technology and GenomicsAlysson Renato Muotri9. Association StrategiesBenjamin M. Neale10. The promise of Systems BiologyEric Schadt11. Gene networks in neuropsychiatric diseaseDaniel Geschwind12. MosaicismChristopher A. Walsh and Saumya Shekhar Jamuar Section 2 A new neuroanatomy13. Mapping the Molecular Landscape of the Human BrainNenad Sestan14. Studying CircuitsStephan Lammel and Robert Malenka 15. Electrophysiological Measurement of CircuitsSrikantan S. Nagarajan16. Imaging the Circuitry of the Human BrainMichael Greicius17. Neuroimaging Advances in Alzheimer’s Disease Daniel R. Schonhaut and Gil Rabinovici 18. Progressive Supranuclear Palsy and Related Parkinsonian DisordersJesse A. Brown and William Seeley 19. The Anatomy of Basal Ganglia Circuitry of BehaviorNicholas Au Yong, Adrienne M. Keener, Yvette Bordelon, Carlos Portera-Cailliau and Nader Pouratian 20. Brainstem Circuitry of BehaviorHelmut Heisen21. Apathy – Basal Ganglia, Frontal CircuitsMario F. Mendez22. Emotion CircuitryRobert Wayne Levenson23. DelusionsGeorges Naasan24. HallucinationsDennis VelakoulisSection 3 Clinical Phenomenology25. Intro: Risk Overlap Among DisordersPatrick Sullivan26. The conundrum of Clinical Characterization RDOC/ICD-10/DSMBruce N. Cuthbert27. SchizophreniaAiden Corvin28. PsychosisRaquel E. Gur and Ruben Gur 29. ASDRebecca Ann Muhle, Stephan Sanders, Hannah Reed and Matthew William State 30. Bipolar DisorderNelson B. Freimer, Carrie E. Bearden and Peter Zandi 31. MDDDavid C. Glahn32. Speech and Language DisordersMarilu Gorno-Tempini33. Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal DementiaSuzee Eurie Lee and Jennifer S. Yokoyama 34. Alzheimer’sRudy Tanzi35. PTSDKerry Ressler36. Neurodevelopmental syndromesElliott Sherr37. EpilepsiesRyan S. Dhindsa, Daniel Lowenstein and David Goldstein 38. Substance AbuseNii Addy39. NeuroimmunologyEmmanuel Mignot40. Brain TumorsVanessa Clark and Murat Günel 41. White Matter DisordersMichael David Geschwind and Brianne Magouirk Bettcher 42. ALSElena Ratti and James Berry 43. Eating DisordersCynthia M. Bulik and Garret Stuber Section 4 Clinical Translation and Drug Development44. PharmacogenomicsRoy H. Perlis